Filling the Gap for High-Risk Patients: PIONEER TAVR® Transcatheter Aortic Valve System Approved by NMPA

Product Overview

This innovative system from KOKA Lifesciences focuses on the precise clinical needs of elderly, high-risk patients suffering from symptomatic, severe aortic valve insufficiency (severe aortic regurgitation). It serves as a vital micro-invasive alternative for patients aged 70 and older who are deemed unsuitable for conventional open-heart surgical valve replacement.

System Components & Performance

• Prosthetic Valve: Constructed from bovine pericardium leaflets for superior anti-calcification and biocompatibility. It features a self-expanding nitinol frame for excellent sealing and a platinum-iridium radiopaque ring for precise intraoperative positioning.
• Delivery System: Equipped with a hydrophilic coating to reduce intravascular friction and complications, ensuring smooth device navigation.
• Global Firsts: The system introduces world-first stent positioning wire support technology and two-stage 3D space steerable technology for unprecedented control during deployment.

Clinical Significance

The PIONEER TAVR® fills a critical gap in the Chinese domestic market for treating pure native aortic regurgitation. Clinical data indicates stable hemodynamics and significant, sustained improvements in the quality of life and functional status for high-risk patients following the procedure.